Insmed's lung drug meets main goal in late-stage study
Insmed Inc said its drug for the treatment of a rare and serious lung disorder met the main goal in a late-stage study, sending its shares up 75 percent in premarket trading on Tuesday.
The company said the addition of the drug, Alis, to basic therapy showed statistical significance in reducing the lung disease by the sixth month in 29 percent of patients, compared with 9 percent in patients on basic treatment.
(This article has not been edited by Zeebiz editorial team and is auto-generated from an agency feed.)
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.